SCHEMBL17549650

SCHEMBL17549650

CCN(CC)CCC(=O)c1ccc(C(C)C)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.60
THRA P10827 3/20 0.46
THRB P10828 3/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.43
TSHR P16473 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
SLC22A2 O15244 1/20 0.42
SLC22A1 O15245 1/20 0.42
ACHE P22303 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAOA P21397 1/20 0.42
HTR3A P46098 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5953952 0.83 GSK3B (0.53) THRATHRBKMT2AMEN1ALDH1A1
SCHEMBL9491562 0.83 LMNA (0.59) THRATHRBKMT2ATSHRALDH1A1
SCHEMBL30089581 0.82 USP5 (0.85) USP5KMT2AMEN1POLBHPGD
SCHEMBL17549669 0.81 KMT2A (0.56) THRATHRBKMT2AMEN1ALDH1A1
SCHEMBL11464173 0.80 USP5 (0.70) USP5KMT2AMEN1POLBHPGD
SCHEMBL5954012 0.79 HTR7 (0.61) THRATHRBKMT2APOLBTSHR
SCHEMBL6322827 0.79 KMT2A (0.67) THRATHRBKMT2AMEN1POLB
SCHEMBL4871741 0.78 USP5 (0.72) USP5KMT2AMEN1POLBL3MBTL1
SCHEMBL5566974 0.77 USP5 (0.66) USP5THRATHRBKMT2AMEN1
Hydrochloric Acid SCHEMBL10670271 0.77 KMT2A (0.65) THRATHRBKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160060235-A1 Therapeutic Agent for Type 2 Diabetes NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060235-A1 Therapeutic Agent for Type 2 Diabetes RNASE1, CDKL2, CDKL1 USP5 1349/4885THRA 1897/4885THRB 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.